Structural basis for high-affinity peptide inhibition of human Pin1.

Human Pin1 is a key regulator of cell-cycle progression and plays growth-promoting roles in human cancers. High-affinity inhibitors of Pin1 may provide a unique opportunity for disrupting oncogenic pathways. Here we report two high-resolution X-ray crystal structures of human Pin1 bound to non-natural peptide inhibitors. The structures of the bound high-affinity peptides identify a type-I beta-turn conformation for Pin1 prolyl peptide isomerase domain-peptide binding and an extensive molecular interface for high-affinity recognition. Moreover, these structures suggest chemical elements that may further improve the affinity and pharmacological properties of future peptide-based Pin inhibitors. Finally, an intramolecular hydrogen bond observed in both peptide complexes mimics the cyclic conformation of FK506 and rapamycin. Both FK506 and rapamycin are clinically important inhibitors of other peptidyl-prolyl cis-trans isomerases. This comparative discovery suggests that a cyclic peptide polyketide bridge, like that found in FK506 and rapamycin or a similar linkage, may significantly improve the binding affinity of structure-based Pin1 inhibitors.

[1]  A. Tanaka [A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[2]  Xiao Zhen Zhou,et al.  Targeting carcinogenesis: A role for the prolyl isomerase Pin1? , 2006, Molecular carcinogenesis.

[3]  F. Etzkorn Pin1 flips Alzheimer's switch. , 2006, ACS chemical biology.

[4]  Xiao Zhen Zhou,et al.  Nanomolar inhibitors of the peptidyl prolyl cis/trans isomerase Pin1 from combinatorial peptide libraries. , 2006, Journal of medicinal chemistry.

[5]  A. Ryo,et al.  Pin1 Regulates Centrosome Duplication, and Its Overexpression Induces Centrosome Amplification, Chromosome Instability, and Oncogenesis , 2006, Molecular and Cellular Biology.

[6]  G. Fischer,et al.  Pharmacological targeting of catalyzed protein folding: the example of peptide bond cis/trans isomerases. , 2006, Handbook of experimental pharmacology.

[7]  Akira Yamaguchi,et al.  Stable Suppression of Tumorigenicity by Pin1-Targeted RNA Interference in Prostate Cancer , 2005, Clinical Cancer Research.

[8]  W. Park,et al.  Pin1 overexpression in colorectal cancer and its correlation with aberrant beta-catenin expression. , 2005, World journal of gastroenterology.

[9]  K. Lu,et al.  Phosphorylation-specific prolyl isomerization: is there an underlying theme? , 2005, Nature Cell Biology.

[10]  Priti Garg,et al.  Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis , 2004, The EMBO journal.

[11]  R. Sears The Life Cycle of C-Myc: From Synthesis to Degradation , 2004, Cell cycle.

[12]  J. Sowadski,et al.  Prevalent overexpression of prolyl isomerase Pin1 in human cancers. , 2004, The American journal of pathology.

[13]  Masahiro Ito,et al.  Cyclin D1 overexpression in thyroid tumours from a radio‐contaminated area and its correlation with Pin1 and aberrant β‐catenin expression , 2004, The Journal of pathology.

[14]  D. Dominguez-Sola,et al.  PINning down the c-Myc oncoprotein , 2004, Nature Cell Biology.

[15]  Anna Frolov,et al.  The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. , 2003, Cancer research.

[16]  H. Namba,et al.  Cyclin D1 Overexpression in Thyroid Tumors from the Radio-contaminated Area, and its Correlation with Pin1 and Aberrant beta-Catenin Expressions , 2003 .

[17]  S. Volinia,et al.  The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults , 2002, Nature.

[18]  S. Murray,et al.  The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response , 2002, Nature.

[19]  U. Reimer,et al.  Substrate-based design of reversible Pin1 inhibitors. , 2002, Biochemistry.

[20]  Y. Liou,et al.  Pinning down proline-directed phosphorylation signaling. , 2002, Trends in cell biology.

[21]  T. Hunter,et al.  Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Tianhua Niu,et al.  Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c‐Jun towards cyclin D1 , 2001, The EMBO journal.

[23]  M. Kirschner,et al.  Pin1 acts catalytically to promote a conformational change in Cdc25. , 2001, Molecular cell.

[24]  G N Murshudov,et al.  Use of TLS parameters to model anisotropic displacements in macromolecular refinement. , 2001, Acta crystallographica. Section D, Biological crystallography.

[25]  Masafumi Nakamura,et al.  Pin1 regulates turnover and subcellular localization of β-catenin by inhibiting its interaction with APC , 2001, Nature Cell Biology.

[26]  G Fischer,et al.  Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. , 2000, Molecular cell.

[27]  Tony Hunter,et al.  Structural basis for phosphoserine-proline recognition by group IV WW domains , 2000, Nature Structural Biology.

[28]  A. Schnapp,et al.  Phosphorylation-dependent proline isomerization catalyzed by Pin1 is essential for tumor cell survival and entry into mitosis. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[29]  Xiao Zhen Zhou,et al.  Function of WW domains as phosphoserine- or phosphothreonine-binding modules. , 1999, Science.

[30]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[31]  U. Reimer,et al.  Mapping the stereospecificity of peptidyl prolyl cis/trans isomerases , 1998, FEBS letters.

[32]  M. Kirschner,et al.  Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. , 1997, Science.

[33]  M. Schutkowski,et al.  A protease-free assay for peptidyl prolyl cis/trans isomerases using standard peptide substrates. , 1997, Analytical biochemistry.

[34]  Stephen W. Byers,et al.  Serine Phosphorylation-regulated Ubiquitination and Degradation of β-Catenin* , 1997, The Journal of Biological Chemistry.

[35]  R. Ranganathan,et al.  Structural and Functional Analysis of the Mitotic Rotamase Pin1 Suggests Substrate Recognition Is Phosphorylation Dependent , 1997, Cell.

[36]  S. Byers,et al.  Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. , 1997, The Journal of biological chemistry.

[37]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[38]  T. Hunter,et al.  A human peptidyl–prolyl isomerase essential for regulation of mitosis , 1996, Nature.

[39]  F. Schmid,et al.  Protein folding: Prolyl isomerases join the fold , 1995, Current Biology.

[40]  L. Pinna,et al.  Efficient Fmoc/solid-phase peptide synthesis of O-phosphotyrosyl-containing peptides and their use as phosphatase substrates. , 2009, International journal of peptide and protein research.

[41]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[42]  G. Fischer,et al.  A novel peptidyl‐prolyl cisltrans isomerase from Escherichia coli , 1994, FEBS letters.

[43]  J. Navaza,et al.  AMoRe: an automated package for molecular replacement , 1994 .

[44]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[45]  J. Kofron,et al.  A continuous spectrophotometric direct assay for peptidyl prolyl cis-trans isomerases. , 1993, Biochemical and biophysical research communications.

[46]  A. Brünger Free R value: a novel statistical quantity for assessing the accuracy of crystal structures , 1992, Nature.

[47]  J. Perich,et al.  Fmoc/solid-phase synthesis of Tyr(P)-containing peptides through t-butyl phosphate protection. , 2009, International journal of peptide and protein research.

[48]  D. M. Andrews,et al.  Solid-phase synthesis of a range of O-phosphorylated peptides by post-assembly phosphitylation and oxidation. , 2009, International journal of peptide and protein research.

[49]  J. Kofron,et al.  Determination of kinetic constants for peptidyl prolyl cis-trans isomerases by an improved spectrophotometric assay. , 1991, Biochemistry.

[50]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[51]  Nolan H. Sigal,et al.  A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin , 1989, Nature.

[52]  S. Schreiber,et al.  A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase , 1989, Nature.

[53]  T. Kiefhaber,et al.  Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins , 1989, Nature.

[54]  T. Hayano,et al.  Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin , 1989, Nature.

[55]  K. Wüthrich NMR of proteins and nucleic acids , 1988 .

[56]  P. Baine Comparison of rate constants determined by two‐dimensional NMR spectroscopy with rate constants determined by other NMR techniques , 1986 .

[57]  D. Speicher,et al.  Cyclophilin: a specific cytosolic binding protein for cyclosporin A. , 1984, Science.